1,058 results on '"Freedland, Stephen"'
Search Results
2. PD03-05 DOES INSULIN RESISTANCE CREATE A BIGGER PROSTATE? RESULTS FROM THE REDUCTION BY DUTASTERIDE OF PROSTATE CANCER EVENTS (REDUCE) TRIAL
3. MP24-05 NARRATIVE CONTENT OF PATIENTS DURING MULTIDISCIPLINARY CONSULTATIONS FOR CLINICALLY LOCALIZED PROSTATE CANCER
4. PD61-01 SPECIALTY BIAS IN REPORTING OF ADVANTAGES AND DISADVANTAGES OF TREATMENT OPTIONS IN CONSULTATIONS FOR EARLY STAGE PROSTATE CANCER
5. MP12-13 WHAT WOULD YOU DO IF IT WERE YOU, DOC?: PATIENT AND PHYSICIAN PERSPECTIVES ON WHY PROSTATE CANCER PATIENTS SEEK “PERSONAL ADVICE” FROM PROVIDERS AND HOW PHYSICIANS RESPOND
6. MP12-12 PHYSICIAN PREFERENCES REGARDING COMMUNICATION OF LIFE EXPECTANCY IN PROSTATE CANCER TREATMENT CONSULTATIONS
7. PD48-05 USE OF BLUE LIGHT CYSTOSCOPY AMONG NON-MUSCLE INVASIVE BLADDER CANCER PATIENTS AND OUTCOMES IN AN EQUAL ACCESS SETTING: A PROPENSITY SCORED MATCHED ANALYSIS
8. MP24-03 DEVELOPMENT AND VALIDATION OF A NATURAL LANGUAGE PROCESSING SYSTEM TO IDENTIFY INFORMATION ON KEY TRADEOFFS IN PROSTATE CANCER TREATMENT CONSULTATIONS
9. MP24-01 INTEGRATING NATURAL LANGUAGE PROCESSING WITH CHATGPT TO IMPROVE QUALITY OF ARTIFICIAL INTELLIGENCE SUMMARIES OF PROSTATE CANCER CONSULTATIONS
10. PD62-05 PATIENT PERCEPTIONS OF STANDARDIZED RISK LANGUAGE USED IN AMERICAN COLLEGE OF RADIOLOGY PROSTATE MRI PIRADS SCORES
11. MP34-01 BASELINE PROSTATE-SPECIFIC ANTIGEN SCREENING VALUES IN TRANSGENDER WOMEN ON GENDER-AFFIRMING HORMONE THERAPY: A NATIONAL COHORT STUDY
12. MP60-02 REAL WORLD TREATMENT SEQUENCE AND SURVIVAL IN LOCALIZED OR LOCALLY ADVANCED PROSTATE CANCER AND POSTPROGRESSION DISEASE STATES
13. MP58-18 DOES EQUAL ACCESS MEAN EQUAL ACCESS TO SECONDARY TREATMENTS AFTER BIOCHEMICAL RECURRENCE (BCR) FOLLOWING RADICAL PROSTATECTOMY (RP)
14. PD29-01 DOES INSULIN RESISTANCE PREDICT AGGRESSIVE PROSTATE CANCER? RESULTS FROM THE REDUCTION BY DUTASTERIDE OF PROSTATE CANCER (REDUCE) TRIAL
15. PD01-06 PROSTATE-SPECIFIC ANTIGEN DYNAMICS FROM THE PHASE 3 EMBARK TRIAL: A POST HOC ANALYSIS
16. Serum Testosterone and Dihydrotestosterone and Incidence and Progression of Lower Urinary Tract Symptoms: Results From the REDUCE Study
17. Serum Testosterone and Dihydrotestosterone and Incidence and Progression of Lower Urinary Tract Symptoms: Results From the REDUCE Study.
18. PD02-06 SERUM TESTOSTERONE AND DIHYDROTESTOSTERONE AND INCIDENCE AND PROGRESSION OF LOWER URINARY TRACT SYMPTOMS IN REDUCTION BY DUTASTERIDE OF PROSTATE CANCER EVENTS TRIAL
19. MP38-01 PATIENT-LEVEL VALIDATION OF LIFE EXPECTANCY CUTOFFS FOR TRIAGE OF AGGRESSIVE TREATMENT BY TUMOR RISK USING TARGETED CROWDSOURCING
20. MP46-01 UNDERSTANDING THE IMPACT OF THE SOCIAL CONSTRUCT OF RACE ON RECEIPT OF RADICAL CYSTECTOMY IN THE LARGEST EQUAL ACCESS HEALTH SYSTEM IN THE US: THE VETERANS AFFAIRS HEALTH SYSTEM
21. MP29-09 IDENTIFICATION OF PROSTATE CANCER METASTATIC DISEASE FOR DIFFERENT RISK GROUPS BASED ON FASTTEXT WORD EMBEDDING AND SUPERVISED LEARNING
22. MP54-02 VARIATION IN CONTENT DISCUSSED BY SPECIALTY IN CONSULTATIONS FOR CLINICALLY LOCALIZED PROSTATE CANCER
23. LBA02-09 EMBARK: A PHASE 3 RANDOMIZED STUDY OF ENZALUTAMIDE OR PLACEBO PLUS LEUPROLIDE ACETATE AND ENZALUTAMIDE MONOTHERAPY IN HIGH-RISK BIOCHEMICALLY RECURRENT PROSTATE CANCER
24. PD16-12 REAL-WORLD OUTCOMES AMONG MEN WITH NONMETASTATIC CASTRATION-SENSITIVE BIOCHEMICAL RECURRENCE AFTER DEFINITIVE THERAPY WITH SHORT PSA DOUBLING TIME RECEIVING EARLY SECONDARY TREATMENT
25. MP29-15 REMOTELY-MONITORED SLEEP MEASURES IN PROSTATE CANCER PATIENTS UNDERGOING ANDROGEN DEPRIVATION THERAPY (ADT)
26. MP67-09 RELATIONSHIP BETWEEN SKIN CANCER AND AGGRESSIVE PROSTATE CANCER: RESULTS FROM THE SEARCH DATABASE
27. PD29-06 ASSOCIATION BETWEEN AGENT ORANGE EXPOSURE AND RISK OF BLADDER CANCER: A NATIONWIDE COHORT STUDY
28. PD21-07 RACIAL IMPACT (ASIAN VS. WHITE) ON THE PROGNOSIS OF PATIENTS WITH DE NOVO MCSPC: AN ANALYSIS ON LATITUDE, SEER AND NCDB
29. MP76-19 INVESTIGATING NATIONAL TRENDS IN INTEREST FOR BENIGN PROSTATIC HYPERPLASIA SURGERY OPTIONS USING GOOGLE TRENDS
30. PD29-11 DISPARITIES IN STAGE AT DIAGNOSIS AMONG BLACK BLADDER CANCER PATIENTS IN THE LARGEST EQUAL ACCESS HEALTH SYSTEM IN THE US: THE VETERANS AFFAIRS HEALTH SYSTEM
31. PD20-04 TRENDS IN PROSTATE CANCER DIAGNOSIS IN TRANSGENDER WOMEN: A NATIONAL STUDY
32. MP20-02 27 HYDROXYCHOLESTEROL AND DNA DAMAGE REPAIR: IMPLICATIONS IN PROSTATE CANCER
33. MP77-15 INCREASED RISK OF BIOCHEMICAL RECURRENCE AFTER RADICAL PROSTATECTOMY IN THE ACTIVE SURVEILLANCE ERA
34. MP19-11 RACIAL AND ETHNIC DISPARITIES IN VALUATION OF LIFE EXPECTANCY IN PROSTATE CANCER TREATMENT DECISION MAKING
35. Editorial Comment
36. Food Sensitivities in a Diverse Nationwide Cohort of Veterans With Interstitial Cystitis/Bladder Pain Syndrome
37. Variation in Communication of Competing Risks of Mortality in Prostate Cancer Treatment Consultations
38. MP39-02 LONG TERM COST COMPARISONS OF RADICAL CYSTECTOMY VERSUS TRIMODAL THERAPY FOR MUSCLE-INVASIVE BLADDER CANCER
39. MP57-03 IS ADVERSE PATHOLOGY AT THE TIME OF RADICAL PROSTATECTOMY A USEFUL PREDICTOR OF LONG-TERM OUTCOMES IN ACTIVE SURVEILLANCE CANDIDATES? RESULTS FROM THE SEARCH COHORT
40. PD08-06 PREVALENCE OF URGE URINARY INCONTINENCE AMONG WOMEN WITH INTERSTITIAL CYSTITIS/BLADDER PAIN SYNDROME
41. PD25-06 VARIATION IN COMMUNICATION OF COMPETING RISKS OF MORTALITY IN PROSTATE CANCER TREATMENT CONSULTATIONS
42. MP03-13 IDENTIFICATION OF MUSCLE-INVASION STATUS IN BLADDER CANCER PATIENTS USING NATURAL LANGUAGE PROCESSING AND MACHINE LEARNING
43. MP31-14 VARIATION IN COMMUNICATION OF SIDE EFFECTS IN PROSTATE CANCER TREATMENT CONSULTATIONS
44. PD13-10 DIABETES AND PROSTATE CANCER OUTCOMES IN MEN WITH NONMETASTATIC CASTRATE-RESISTANT PROSTATE CANCER: RESULTS FROM THE SEARCH COHORT
45. MP28-11 IMPLICIT BIAS IN COMMUNICATION OF RISK IN PROSTATE CANCER TREATMENT CONSULTATIONS
46. PD54-05 HALSTEADIAN VIEW OF PROSTATE CANCER: DOES REMOVING MORE NODES AT RADICAL PROSTATECTOMY AFFECT BIOCHEMICAL RECURRENCE?
47. Association between Delay to Radical Prostatectomy and Clinically Meaningful Outcomes among Patients with Intermediate and High-Risk Localized Prostate Cancer
48. Development and Validation of an Improved Pathological Nodal Staging System in Men with Prostate Cancer
49. Management of Patients with Metastatic Castration-Sensitive Prostate Cancer in the Real-World Setting in the United States
50. Low Carbohydrate Diets and Estimated Cardiovascular and Metabolic Syndrome Risk in Prostate Cancer
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.